TickerTalks
Browse all tickers →
TickerTalks›$QURE
QUQURE

uniQure N.V.

$QURE·$3.1B·Biotechnology·Healthcare
$42.49-1.4%YTD+76.8%1Y+193.6%
Price updated 12h ago·X counts updated 4d ago
QUQURE
$QUREuniQure N.V.
$42.49-1.42%149 posts0.9×
AI analysisFundamentalsVoices on X
Loading…

On X

The complete picture of $QURE on X — how loud the conversation is right now, how it has trended over the last two weeks, and which way the crowd is leaning.

149X posts · last 7 days
Aug 30Sep 12
Chatter Meter
0.9×
QuietNormal · 1×Loud

How loud $QURE's conversation on X is versus its own normal — 1× is typical, higher means busier. Right now it's about its usual level.

Bullish sentimentAI analysisGenerated by AI from underlying data14 posts analyzed · as of 2026-09-16

uniQure posters are stacking optionality into the AMT-130 4-year Huntington's readout, expected at the October Cell & Gene Meeting on the Mesa. Mizuho previewed continued durability, Dr. Victor Sung's public confidence gets highlighted as the tell, and roughly 2,100 October $55 calls traded (~$640-700K premium). Bulls note 32 open jobs (up from 3-4 months ago) and Karim Mikhail as the CBER Acting Director as fresh regulatory-friendly context. Nobody in the window is short.

Read what X is saying about $QURE

  • Bullish vs bearish call — with the AI summary of the day's posts
  • Divergence flag when the top-engagement posts argue the other side
  • How loud the conversation is versus this ticker's own normal
Free, forever. No credit card.

AI verdictAI analysisGenerated by AI from underlying data

TickerTalks' own read on what's driving $QURE — fundamentals, momentum, or an event — and whether it agrees with the X crowd.

Hinges on a big eventEvent coming upAI verdict · as of 2026-09-17

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Huntington's-disease gene therapy just filed for FDA approval — the October readout is the whole trade.

uniQure is a Dutch clinical-stage biotech behind Hemgenix (hemophilia B gene therapy, marketed by CSL) and AMT-130 for Huntington's disease — the pipeline is the story, and Huntington's is the whole trade. Shares are up 77% YTD and 194% year-on-year on the fresh BLA filing.

  • The financial baseline is pre-commercial: Q1 revenue was $3.6M with a -1,243% operating margin and $38M FCF burn — this is not a P&L story, it's a value-at-approval optionality trade priced against the AMT-130 dataset.
  • The catalyst calendar is specific: BLA submitted Sept 2 for AMT-130 with accelerated approval requested, the 4-year Huntington's readout is expected at the October Cell & Gene Meeting on the Mesa, Mizuho previewed durability, and ~2,100 October $55 calls traded (~$640-700k premium) — options flow tracking a specific window.

The October readout and BLA acceptance decision are the switches — a positive 4-year data print plus a formal BLA acceptance breaks the run further, while durability erosion or an FDA refuse-to-file is what would reset the story. Karim Mikhail as CBER Acting Director is a real regulatory-friendly context tailwind.

Agrees with X sentimentLine up with the bullish X read — the 4-year AMT-130 readout at October Cell & Gene, Mizuho durability preview, Dr. Sung's public confidence, and the specific October $55 call flow all track real institutional positioning. The 32 open jobs (up from 3-4) is a fair operational signal.

What to watch: October Cell & Gene Meeting on the Mesa AMT-130 4-year readout, FDA BLA acceptance decision, and Nov 9 Q3 earnings. A positive readout plus BLA acceptance carries the run further; durability erosion or a refuse-to-file resets the story.

On the calendar: 2026-11-09 — Q3 2026 earnings

Read the AI verdict on $QURE

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • Whether TickerTalks' read agrees with or diverges from the X crowd
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Gene therapy company with hemophilia B therapy (etranacogene) in pivotal trials and AMT-130 for Huntington's disease.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $QURE.

Biotechnology · Healthcare

mRNA oncology platform is the week's catalyst — Merck CEO hinted positive MRNA melanoma Phase 3 data (Oct readout, potentially doubling cancer-free rate vs Keytruda), driving MRNA +8%. IBB +41% T12M reflects the GLP-1, gene-editing, and RNA-medicine premium multiples re-rating the sector. ALT +14.2% since earnings confirms GLP-1 pipeline names as the most active near-term catalyst cohort.

What this means for $QURE

Partial — gene therapy for hemophilia B (etranacogene) and Huntington's disease (AMT-130) benefits from the gene-therapy premium multiples driving the sector re-rating; rare disease binary readouts are the company-specific catalyst.

Top industry ETF

$IBBiShares Biotechnology ETF
+19.3%YTD
+43.6%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-14.5How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-26.5%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-10.6%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-5.7%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
167.9Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-146%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
74.1%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.4Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Jul 29, 2026$-1.22$-0.82-48.4%
Q1 2026May 5, 2026$-0.85$-0.88+3.4%
Q4 2025Mar 2, 2026$-0.56$-0.93+39.8%
Q3 2025Nov 10, 2025$-1.38$-0.85-62.4%
Next earningsMon, Nov 9·consensus EPS $-0.84

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$3.6M+127.3%93.9%-1243%$-0.85$-38.4M
Q4 FY25$5.6M+6.6%38.8%-937%$-0.59$-77.2M
Q3 FY25$3.7M+61.8%89.2%-1379%$-1.38$-16.3M
Q2 FY25$5.3M-52.7%87.5%-834%$-0.69$-40.2M

Forward consensus

5-year forecast · up to 9 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$22.3M$17.7M – $28.6M-$3.92-$4.24 – -$3.649
FY27$135.3M$70.0M – $260.6M-$3.05-$3.46 – -$2.448
FY28$408.6M$96.3M – $787.7M-$1.12-$4.24 – $3.118
FY29$652.6M$181.5M – $1.4B$1.20$0.07 – $2.976
FY30$882.1M$245.3M – $1.9B$3.86$0.24 – $9.586

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.1×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.54%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-4.4%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+46.9%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 62.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today2.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.945-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJul 2Matthew C KapustaCEO21.1K sh$952KSellJun 30Jack KayeDirector21.2K sh$983KSellJun 30Walid Abi-saabChief Medical Officer30.0K sh$1.4MSellJun 26Walid Abi-saabChief Medical Officer1.4K sh$67KSellJun 25Matthew C KapustaCEO28.7K sh$1.4MSellJun 24Matthew C KapustaCEO6.7K sh$335KSellJun 18Matthew C KapustaCEO41.7K sh$2.1MSellJun 17Jack KayeDirector5.3K sh$225KSellJun 17Madhavan BalachandranDirector11.7K sh$526KSellJun 17Matthew C KapustaCEO164.4K sh$7.3M
1–10 of 23
+ 20 other (13 exempts · 7 awards) in window

See when $QURE insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDSep 28-K — Item 7.01: Press release / Reg FD
AI summary

uniQure (QURE) filed an 8-K (Item 8.01) announcing submission of a Biologics License Application (BLA) to the FDA for AMT-130, its gene therapy for Huntington's disease, seeking accelerated approval. This is a regulatory milestone. FDA acceptance and PDUFA date were not yet disclosed in the excerpt.

8-KMaterial agreementJun 248-K — Item 1.01: Material agreement · Item 8.01: Other event
AI summary

uniQure N.V. entered an underwriting agreement on June 23, 2026 for a public offering of 4,945,055 ordinary shares at $45.50/share. The underwriter greenshoe option (741,758 additional shares) was exercised in full on June 24, 2026. Total net proceeds estimated at ~$242.7M after underwriting discounts and expenses. Material — confirms the capital raise details; proceeds fund gene therapy pipeline and potential commercialization of DT120.

424B5Prospectus supplement (offering)Jun 24424B5
AI summary

uniQure N.V. priced a public offering of 4,945,055 ordinary shares at $45.50 per share on June 23, 2026, raising ~$225M gross (~$211.5M net), with underwriters led by Leerink Partners. The greenshoe option of 741,758 additional shares was exercised in full on June 24, 2026, bringing total net proceeds to ~$242.7M. Material dilution event at a discount to the prior day's close of $49.04; proceeds will fund gene therapy R&D and potential DT120 commercialization preparation.

424B5Prospectus supplement (offering)Jun 22424B5
AI summary

QURE filed a 424B5 prospectus supplement on 2026-06-22 of 150,000,000 Ordinary Shares at $44.39 per share. This represents dilution happening now.

8-KPress release / Reg FDJun 228-K — Item 7.01: Press release / Reg FD · Item 8.01: Other event
AI summary

The Netherlands ​ ​ ​ 001-36294 ​ ​ ​ N/A disclosed: pursuant to Section 13(a) of the Exchange Act. ☐ ​ ​ ​ Item 7.01 Regulation FD Disclosure. On June 19, 2026, uniQure N.V. (the “ Company ”) issued a press release announcing preliminary data on the first cohort in the Company’s Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mesial temporal lobe epilepsy. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. ​ The information provided in th.

8-KOfficer or director changeJun 158-K — Item 5.02: Officer or director change · Item 5.03: Charter amendment · Item 5.07: Shareholder vote
AI summary

uniQure N.V. filed an 8-K (Items 5.02, 5.03, 5.07) dated June 10, 2026, reporting officer/director changes, an amendment to articles of incorporation or bylaws, and shareholder vote results from its annual meeting. The excerpt is cover-page only with no specifics on which directors/officers changed or what bylaw amendment was approved. The combination of governance changes and a charter amendment may reflect board refreshment or structural changes relevant to uniQure's clinical-stage gene therapy programs.

8-KPress release / Reg FDApr 308-K — Item 7.01: Press release / Reg FD
AI summary

uniQure N.V. filed an 8-K under Item 7.01 (Reg FD) on April 30, 2026, furnishing an investor presentation for this Netherlands-based gene therapy company. The excerpt is XBRL boilerplate with no topic or slide content visible. Routine Reg FD disclosure — for a clinical-stage biotech like uniQure, investor presentations often include pipeline updates and clinical data readouts, making the attached exhibit potentially relevant for AMT-130 (Huntington's) development timeline watchers.

+ 18 other (8 13Gs · 2 10-Qs · 2 earnings 8-Ks · 2 proxys) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

QURE Submits Application for Gene Therapy for Huntington's Diseasezacks.com·14d ago15 Stocks to Watch With Short Squeeze Potentialschaeffersresearch.com·15d agouniQure Filed for Huntington's Approval. Acceptance Is the Catalyst, Analyst Saysbenzinga.com·15d agouniQure seeks US approval for Huntington's gene therapy after FDA reversalreuters.com·15d agouniQure Announces Submission of Biologics License Application for Ifezuntirgene Inilparvovec (AMT-130) in Huntington's Diseaseglobenewswire.com·15d ago

In themes

Explore the broader themes this ticker is being talked about under.

Gene Editing & CRISPR

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$ALT$MRNA$AURA$NWBO$IBRX$SLS$IOVA$CMPS
Voices on X · last 7 days

No standout posts about $QURE on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport